Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-O-hexyldiglycerol is a short-chain alkylglycerol (AG) that acts as a transient and reversible blood-brain barrier (BBB) opening agent. It is primarily utilized as a drug delivery adjuvant to facilitate the penetration of therapeutic compounds, ranging from small molecules like methotrexate to large proteins such as globulins and antibodies, into the brain parenchyma. The mechanism of action involves increasing paracellular permeability by inducing the redistribution of tight junction-associated proteins, including claudin-5 and β-catenin, and potentially modulating the endothelial cytoskeleton. Research indicates that its effects are short-lived and do not permanently disrupt the complexity of tight junction strands, making it a promising tool for overcoming the BBB in the treatment of brain tumors and other central nervous system disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-O-hexyldiglycerol.